Why ASX private health shares aren't as good as they look

Here's why I don't like the future prospects of ASX private health stocks like Medibank Private Ltd (ASX: MPL)

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From my humble observations, Australians seem to enjoy a love/hate relationship with private health insurance. It's always nice flashing your card when you visit the dentist or physio, but paying those weekly or monthly premiums is a bit of a hassle (to put it mildly).

What's more, private health premium costs are one of those things that just seem to keep on rising – usually well above inflation and the cost of living as well.

So with that in mind, you would think private health is a ripe place to invest these days. The sector enjoys widespread use and acceptance as a 'backup' to the publicly funded Medicare. Not only that, there are significant government incentives for individuals (particularly on higher incomes) to take out private health insurance – along with penalties for those who don't.

Most companies don't enjoy that kind of public assistance – in fact, having the government herd customers into your arms is something most businesses can only dream of. Reviewing the performance of the ASX's 2 largest private health insurers, it looks on first glance as though private health is a no-brainer.

Medibank Private Ltd (ASX: MPL) shares have only been on the public markets since its privatisation in 2014 at around $2 per share. Today, MPL shares are going for $3.36 (at the time of writing) and come with a 3.88% dividend yield. A dividend yield that has been steadily increasing since 2014 to boot!

It's a similar story with NIB Holdings Limited (ASX: NHF). NHF shares were asking around $1.30 10 years ago, but today will set you back $6.92, with a 3.89% dividend yield. NIB's dividend payouts have also been steadily increasing over the past decade.

The problem with private health

Before you get the cheque book out, I think it's worth noting that past performance is no indication of the future. As a matter of fact, I believe that things aren't looking so rosy from here.

We have a rapidly ageing population in Australia, which means that over time there will be less healthy, younger people to pay for the higher medical needs of the older generations.

That means rising premiums.

Rising premiums in turn mean there is less incentive for younger people to take out the health insurance in the first place. This has the potential to become a vicious cycle for the fund providers, if it isn't happening already.

Foolish takeaway

Whilst I love both Medibank's and NIB's management and past performance, I think there are significant structural issues for this space as a whole going forward. These issues make me disinclined to pursue this industry for my own portfolio – at least until I can see a clearer path towards the system's sustainability.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A red heart-shaped balloon floats up above the plain white ones, indicating the best shares.
Healthcare Shares

Heart tech firm's shares surge after huge capital raise

A strategic investor has also jumped on board.

Read more »

Lab technician in lab with a tray of specimens
Healthcare Shares

Has this ASX 200 stock just turned the corner after 7% surge?

Brokers think the volatile biotech share can sustain the rally this time.

Read more »

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »